Biotech

Latest Articles

Basilea scores $268M BARDA financing for antifungals, anti-biotics

.Basilea Pharmaceutica's work creating brand new antifungals has obtained a substantial increase com...

Capricor offers Europe civil liberties to late-stage DMD treatment for $35M

.Possessing presently gathered up the united state legal rights to Capricor Therapeutics' late-stage...

FDA fragments adcomm for Applied's unusual condition medication

.After pushing the selection meeting for Applied Therapies' metabolic disorder medicine govorestat, ...

Novo inks $600M NanoVation offer to research genetic drugs ex-liver

.Novo Nordisk is actually continuing its press right into hereditary medicines, agreeing to compensa...

Innovent links cytokine to colon cancer feedbacks

.Innovent Biologics has created the situation that its own gate inhibitor-cytokine blend healthy pro...

Merck, Daiichi ADC strikes target in stage 3 lung cancer cells research study

.A period 3 test of Daiichi Sankyo as well as Merck &amp Co.'s HER3-directed antibody-drug conjugate...

Rakovina grows AI center with collab to select cancer cells intendeds

.5 months after Rakovina Therapeutics turned toward expert system, the cancer-focused biotech has ac...

Ascendis' dwarfism drug smash hits in stage 3, threatens BioMarin

.Ascendis Pharma has emerged as a prospective danger to BioMarin's Voxzogo, mentioning phase 3 growt...

Despite ph. 3 miss out on, Alkeus finds course ahead of time for eye health condition asset

.Though Alkeus Pharmaceuticals' dental eye disease resource fell short to considerably reduce geogra...

Kairos goes social with $6M IPO to fund tests of cancer cells drug

.Along with a trio of biotechs attacking the Nasdaq on Friday, it was very easy to miss out on a sma...

Vaccine and Keytruda combo effective in squamous tissue carcinoma

.Invulnerable gate preventions are actually the superheroes of cancer cells therapy. Drugs like Bris...

Cue Biopharma mark time J&ampJ vet as CBO-- Chutes &amp Ladders

.Invite to today's Chutes &amp Ladders, our summary of considerable leadership hirings, firings and ...

Regeneron's Opdualag rival presents 57% action cost

.Regeneron is back with lasting consequence for its LAG-3 inhibitor as well as PD-1 prevention combo...

AstraZeneca blog posts data on in-house rivals to AbbVie, Pfizer ADCs

.AstraZeneca has shared an early examine the functionality of its in-house antibody-drug conjugate (...

iTeos- GSK's TIGIT celebrity shows significant renovation

.After introducing a period 3 launch based on positive midstage outcomes, iTeos and also GSK are act...

More joint FDA can easily speed up uncommon disease R&ampD: report

.The FDA ought to be actually extra available and also collective to discharge a surge in approvals ...

Zenas, MBX, Bicara head to Nasdaq in very hot time for biotech IPOs

.It's an uncommonly hectic Friday for biotech IPOs, with Zenas BioPharma, MBX and also Bicara Therap...

Atea's COVID antiviral neglects to halt hospital stays in period 3

.Atea Pharmaceuticals' antiviral has actually stopped working an additional COVID-19 trial, yet the ...

Neurocrine's quote to conserve schizophrenia prospect fails

.Neurocrine Biosciences' mental illness system pivot has neglected. The biotech was not able to repr...

Sanofi pays $110M upfront for late-stage radioligand treatment

.Sanofi has actually created an overdue entry to the radioligand event, paying one hundred million e...